Healthcare entity
Citi is most often covered alongside GE HealthCare Technologies, which appears in 1 of these 2 stories. The 14-day window averages about 1 story each week. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category.
Last mentioned: Aug 2, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Citi is most often covered alongside GE HealthCare Technologies, which appears in 1 of these 2 stories. The 14-day window averages about 1 story each week. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. Each story carries 2.5 original sources on average, compared with 3.1 for the broader beat in this window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 2 Healthcare stories that mention Citi, published between March 10, 2026 and March 23, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 320 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Citi. Shared-story counts are live from our verified record — not editorial picks.
Citi has lowered its price target for GE HealthCare Technologies (GEHC), signaling a cautious outlook on the medical imaging giant's near-term growth trajectory. The adjustment reflects broader sector concerns regarding capital equipment spending and regional market volatility in the healthcare technology space.
Source: finance.yahoo.com · insidermonkey.com
Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.
Source: fool.com · Josh Kohn-Lindquist (us)
Citi is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
